Agomelatine-induced hepatotoxicity

Wiener Klinische Wochenschrift

Volumn 125, Issue 7-8, 2013, Pages 225-226

  Štuhec, Matej ^a  

^a Psychiatric Hospital Ormoz   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ESCITALOPRAM; OLANZAPINE; ZOLPIDEM; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; INSOMNIA; LABORATORY TEST; LETTER; LIVER TOXICITY; MOOD DISORDER; PSYCHOPHARMACOTHERAPY; TREATMENT DURATION; TREATMENT RESPONSE; DIFFERENTIAL DIAGNOSIS; TOXIC HEPATITIS; COMPLICATION; DRUG-INDUCED LIVER INJURY; MOOD DISORDERS;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MOOD DISORDERS;

EID: 84891415925     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0344-0     Document Type: Letter

References (10)

1. Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today. 2009;45:599-608.
2. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-Activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double- blind comparison with sertraline. J Clin Psychiatry. 2010;71:109-20.
3. Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709-31.
4. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-55.
5. Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med. 2002;40:718-24.
6. Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 3. Reference procedure for the measurement of catalytic concentration of lactate dehydrogenase. Clin Chem Lab Med. 2002;40:631-4.
7. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebocontrolled trial. J Clin Psychopharmacol. 2010;30:135-44.
8. Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol. 2006;21 Suppl 1:S31-5.
9. De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Rep Psychiatry. 2012;2012:642752.
10. Müller H, Seifert F, Maler JM, et al. Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients. Singapore Med J. 2012;53:e228-30.